Interleukin-2 levels in chronic schizophrenia patients

Area of Science:

• Neuroimmunology
• Psychiatric research
• Biomarker discovery

Background:

• Schizophrenia research has historically focused on Caucasian populations.
• Interleukin activity, specifically IL-2, is implicated in schizophrenia.
• Limited data exists on IL-2 levels in Asian populations with schizophrenia.

Purpose of the Study:

• To investigate serum Interleukin-2 (IL-2) levels in chronic schizophrenia patients of Asian origin.
• To examine the relationship between IL-2 levels, illness duration, psychopathology, and treatment in this cohort.
• To compare IL-2 levels between Asian patients with schizophrenia and healthy Chinese controls.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure phytohemagglutinin-stimulated serum IL-2 production.
• Thirty chronic schizophrenia patients and ten healthy Chinese males were recruited.
• Patients were assessed for symptom severity using the Positive and Negative Syndrome Scale (PANSS), and demographic and medication data were collected.

Main Results:

• Serum IL-2 levels were significantly lower in schizophrenia patients (1327 +/- 596.2) compared to healthy Chinese controls (2420 +/- 342.5).
• This reduction in IL-2 levels was observed across the entire duration of the illness.
• A negative correlation was found between IL-2 levels and illness duration, and a positive correlation with medication dosage.

Conclusions:

• The findings replicate previous observations of reduced IL-2 levels in schizophrenia within an Asian population.
• This study provides novel data on IL-2 levels in Chinese patients with schizophrenia.
• IL-2 may serve as a potential biomarker, influenced by illness duration and medication in this demographic.